Bifidobacterium breve CBT BR3 is effective at relieving intestinal inflammation by augmenting goblet cell regeneration
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von I Seul Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University Coll…. Hauptthemen laut MEDLINE: Bifidobacterium breve, Colitis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Background and Aim Bifidobacterium breve was the first bacteria isolated in the feces of healthy infants and is a dominant species in the guts of breast‐fed infants. Some strains of B. breve have been shown to be effective at relieving intestinal inflammation, but the modes of action have yet to be elucidated. In this study, we investigated the mechanisms of action of B. breve CBT BR3 isolated from South Korean infant feces in relieving colitis in vitro and in vivo.
Methods
Colitis was induced in mice with dextran sodium sulfate (DSS) and dinitrobenzene sulfonic acid (DNBS). Quantitative reverse‐transcription polymerase chain reaction, in vitro FITC‐dextran flux permeability assay, and aryl hydrocarbon receptor (AhR) luciferase assay are performed using Caco‐2 cells and HT29‐Lucia™ AhR cells.
Results
B. breve CBT BR3 was orally administered. B. breve CBT BR3 improved colitis symptoms in both DSS‐ and DNBS‐induced colitis models. B. breve CBT BR3 increased the number of goblet cells per crypt. B. breve increased the mRNA expressions of Notch , Spdef , Muc5 , and Il22 . The mRNA expressions of Occludin , which encodes a membrane tight‐junction protein, and Foxo3 , which encodes a protein related to butyrate metabolism, were also increased in the DSS‐ and DNBS‐induced colitis models. B. breve CBT BR3 protected inflammation‐induced epithelial cell permeability and improved goblet cell function by inducing aryl hydrocarbon receptor in vitro.
Conclusions
These results indicate that B. breve CBT BR3 is effective at relieving intestinal inflammation by augmenting goblet cell regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Institute of Gastroenterology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
ORCID-Profile: Jae Hee Cheon
Förderung
- National Research Foundation of Korea (NRF)
Zitieren
APA
Park, I. S., Kim, J. H., Yu, J., Shin, Y., Kim, K., Kim, T. I., Kim, S. W., & Cheon, J. H. (2023). Bifidobacterium breve CBT BR3 is effective at relieving intestinal inflammation by augmenting goblet cell regeneration. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16209
Vancouver
Park IS, Kim JH, Yu J, Shin Y, Kim K, Kim TI, et al. Bifidobacterium breve CBT BR3 is effective at relieving intestinal inflammation by augmenting goblet cell regeneration. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16209
BibTeX
@article{Park2023,
author = {Park, I Seul and Kim, Ji Hyung and Yu, Jongwook and Shin, YooJin and Kim, Kibeom and Kim, Tae Il and Kim, Seung Won and Cheon, Jae Hee},
title = {Bifidobacterium breve CBT BR3 is effective at relieving intestinal inflammation by augmenting goblet cell regeneration},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16209}
}
EUVIMED